Drugs / IZALONTAMAB
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04603287 | Apr 2020 → Dec 2025 overdue | — | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05949606 | Oct 2023 → Dec 2026 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05668858 | Feb 2023 → Dec 2026 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06668961 | Nov 2024 → Nov 2026 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05054439 | Dec 2021 → Dec 2025 overdue | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05022654 | Dec 2021 → Dec 2025 overdue | esophageal squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05020457 | Dec 2021 → Dec 2025 overdue | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05039944 | Nov 2021 → Jun 2022 | colorectal cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05044897 | Oct 2021 → Dec 2025 overdue | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05020769 | Jan 2022 → Dec 2025 overdue | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05943795 | Jul 2023 → Jul 2026 overdue | lung adenocarcinoma, squamous cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IZALONTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095384 ↗ |
| Known as | Her3 x egfr si-b001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095384 ↗ |
| Known as | SI-B001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05039944 ↗ |
| Modality | Monoclonal antibody | “SI-B001, an EGFR/HER3 Bispecific Antibody” NCT04603287 ↗ |
| Route | Intravenous | “Administration by intravenous infusion.” NCT04603287 ↗ |
| Target | EGFR | “SI-B001, an EGFR/HER3 Bispecific Antibody” NCT04603287 ↗ |